Insight Molecular Diagnostics (IMDX) Cash & Current Investments (2015 - 2026)

Insight Molecular Diagnostics has disclosed Cash & Current Investments across 12 years of filings, most recently posting $28.9 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $28.9 million, down 6.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.9 million (down 6.68% YoY), and the FY2025 annual result was $12.3 million, up 42.57% from the prior year.
• Cash & Current Investments came in at $28.9 million for Q1 2026 at Insight Molecular Diagnostics, up from $12.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $45.4 million in Q2 2022 to a low of $866000.0 in Q4 2022.
• The 5-year median for Cash & Current Investments is $14.2 million (2023), against an average of $17.4 million.
• Across the five-year window, Cash & Current Investments sank 97.44% in 2022 and soared 989.15% in 2023, its largest moves.
• Insight Molecular Diagnostics' Cash & Current Investments stood at $866000.0 in 2022, then jumped by 989.15% to $9.4 million in 2023, then retreated by 8.44% to $8.6 million in 2024, then soared by 42.57% to $12.3 million in 2025, then soared by 134.97% to $28.9 million in 2026.
• The last three Cash & Current Investments figures came in at $28.9 million (Q1 2026), $12.3 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.